CervoMed Inc. Files 8-K on Financials

TL;DR

CervoMed dropped an 8-K on financials, check it out.

AI Summary

CervoMed Inc. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition as of August 12, 2024. The filing also included Regulation FD disclosures and financial statements. The company, formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc., is incorporated in Delaware and headquartered in Boston, MA.

Why It Matters

This 8-K filing provides investors with crucial updates on CervoMed's financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate negative news or significant changes.

Key Players & Entities

• CervoMed Inc. (company) — Registrant
• Diffusion Pharmaceuticals Inc. (company) — Former company name
• RestorGenex Corp (company) — Former company name
• Stratus Media Group, Inc (company) — Former company name
• August 12, 2024 (date) — Date of earliest event reported
• August 15, 2024 (date) — Date of report
• 20 Park Plaza, Suite 424 Boston, MA (location) — Company address

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market

Filing Documents

• crvo20240815_8k.htm (8-K) — 33KB
• ex_715402.htm (EX-99.1) — 120KB
• logosm.jpg (GRAPHIC) — 10KB
• 0001437749-24-027012.txt ( ) — 309KB
• crvo-20240812.xsd (EX-101.SCH) — 3KB
• crvo-20240812_def.xml (EX-101.DEF) — 11KB
• crvo-20240812_lab.xml (EX-101.LAB) — 15KB
• crvo-20240812_pre.xml (EX-101.PRE) — 11KB
• crvo20240815_8k_htm.xml (XML) — 3KB

02

Item 2.02 Results of Operations and Financial Condition On August 12, 2024, CervoMed Inc. (the "Company," "we" or "us") issued a press release announcing financial results as of and for the quarter ended June 30, 2024. A copy of that press release is attached hereto as Exhibit99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit99.1) is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act.

01

Item 7.01 Regulation FD Disclosure Certain information concerning the business, clinical studies, development plans, financial position and related matters of the Company has been made available on our website, www.cervomed.com, under the heading, "Investors – Events and Presentations." Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others. The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the Securities and Exchange Commission ("SEC") and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 (including any information incorporated herein by reference) is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of Section 18 of the Exchange Act unless we specifically incorporate it by reference in a document filed under the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or Exchange Act except as set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued August 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 15, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR